Ab cellera stock bot
AbCellera Biologics Inc. (NASDAQ:ABCL) has received an average rating of "Hold" from five analysts currently covering the firm, as reported on March 15, 2026. One analyst issued a sell recommendation, one a hold, and three a buy recommendation. The average 1--year price objective among brokerages is $7.75. Additionally, several large institutional investors have recently adjusted their positions, with UBS AM acquiring a new stake worth approximately $26.94 million in the fourth quarter, and Goldman Sachs Group Inc. increasing its stake by 1,636.3% to 4,344,485 shares valued at $14.86 million.